Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers

Autor: Walker, L.C., Fredericksen, Z.S., Wang, X.S., Tarrell, R., Pankratz, V.S., Lindor, N.M., Beesley, J., Healey, S., Chen, X.Q., Fab, K.C., Stoppa-Lyonnet, D., Tirapo, C., Giraud, S., Mazoyer, S., Muller, D., Fricker, J.P., Delnatte, C., Schmutzler, R.K., Wappenschmidt, B., Engel, C., Schonbuchner, I., Deissler, H., Meindl, A., Hogervorst, F.B., Verheus, M., Hooning, M.J., Ouweland, A.M.W. van den, Nelen, M.R., Ausems, M.G.E.M., Aalfs, C.M., Asperen, C.J. van, Devilee, P., Gerrits, M.M., Waisfisz, Q., Szabo, C.I., Quad, M.S., Easton, D.F., Peock, S., Cook, M., Oliver, C.T., Frost, D., Harrington, P., Evans, D.G., Lalloo, F., Eeles, R., Izatt, L., Chu, C., Davidson, R., Eccles, D., Ong, K.R., Cook, J., Rebbeck, T., Nathanson, K.L., Domchek, S.M., Singer, C.F., Gschwantler-Kaulich, D., Dressler, A.C., Pfeiler, G., Godwin, A.K., Heikkinen, T., Nevanlinna, H., Agnarsson, B.A., Caligo, M.A., Olsson, H., Kristoffersson, U., Liljegren, A., Arver, B., Karlsson, P., Melin, B., Sinilnikova, O.M., McGuffog, L., Antoniou, A.C., Chenevix-Trench, G., Spurdle, A.B., Couch, F.J., Gemo Study Collaborators, HEBON, EMBRACE, SWE BRCA
Přispěvatelé: Easton, Douglas [0000-0003-2444-3247], Antoniou, Antonis [0000-0001-9223-3116], Apollo - University of Cambridge Repository, Division of Genetics and Population Health, Queensland Institute of Medical Research, Department of Laboratory Medicine and Pathology, Mayo Clinic, Pathologie moléculaire des cancers, Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Centre Léon Bérard [Lyon]-Hospices Civils de Lyon (HCL), Génétique moléculaire, signalisation et cancer (GMSC), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Unité d'Oncogénétique, CLCC Paul Strauss, Centre René Gauducheau, Centre for Hereditary Breast and Ovarian Cancer, Department of Obstetrics and Gynaecology-University of Cologne, Institute for Medical Informatics, Statistics and Epidemiology [Leipzig] (IMISE), Universität Leipzig [Leipzig], Institute of Human Genetics, Julius-Maximilians-Universität Würzburg [Wurtzbourg, Allemagne] (JMU), Department of Obstetrics and Gynaecology, Universität Ulm - Ulm University [Ulm, Allemagne], Technische Universität Munchen - Université Technique de Munich [Munich, Allemagne] (TUM)-Klinikum Rechts der Isar-Division of Tumor Genetics, Family Cancer Clinic, The Netherlands Cancer Institute, Department of Epidemiology, Netherlands Cancer Institute, Department of Medical Oncology, Erasmus University Medical Center [Rotterdam] (Erasmus MC)-Family Cancer Clinic, Department of Clinical Genetics, Department of Human Genetics, University Nijmegen Medical Centre, Department of Medical Genetics, University Medical Center [Utrecht], Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC), University of Amsterdam [Amsterdam] (UvA)-University of Amsterdam [Amsterdam] (UvA), Leiden University Medical Center (LUMC), Department of Human Genetics & Department of Pathology, Department of Genetics and Cell Biology, VU University Medical Center [Amsterdam], Strangeways Research Laboratory, University of Cambridge [UK] (CAM)-Department of Public Health and Primary Care-Centre for Cancer Genetic Epidemiology, Centre for Cancer Genetic Epidemiology [Cambridge], Department of Oncology-University of Cambridge [UK] (CAM), Genetic Medicine, St Mary's Hospital-NHS Foundation Trust-Manchester Academic Health Sciences Centre-Central Manchester University Hospitals, Oncogenetics Team, The Institute of Cancer Research-Royal Marsden NHS Foundation Trust, Clinical Genetics Department, Guy's and St Thomas NHS Foundation Trust-Guys Hospital, Yorkshire Regional Genetics Service, St. James's Hospital, Ferguson-Smith Centre for Clinical Genetics, Wessex Clinical Genetics Service, Princess Anne Hospital-Cancer Sciences Division, West Midlands Regional Genetics Service, Birmingham Women's and Children's NHS Foundation Trust, Sheffield Clinical Genetics Service, Sheffield Children's NHS Foundation Trust, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania [Philadelphia]-University of Pennsylvania [Philadelphia], Division of Special Gynecology, Medizinische Universität Wien = Medical University of Vienna-Department of OB/GYN, Women's Cancer Program, Fox Chase Cancer Center, Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Department of Pathology, University Hospital and University of Iceland School of Medicine, Section of Genetic Oncology, University of Pisa - Università di Pisa, Department of Oncology, Lund University Hospital, Karolinska University Hospital [Stockholm], Sahlgrenska University Hospital [Gothenburg], Department of Radiation Sciences and Oncology, Umeå University, kConFab, GEMO Study Collaborators, HEBON, ModSQuaD, EMBRACE, SWE-BRCA, Human Genetics, BMC, Ed., Julius-Maximilians-Universität Würzburg (JMU), University of Cambridge [UK] (CAM)-Department of Oncology, University of Pennsylvania-University of Pennsylvania, Medical Oncology, Clinical Genetics, Gastroenterology & Hepatology, Targeted Gynaecologic Oncology (TARGON), Damage and Repair in Cancer Development and Cancer Treatment (DARE)
Jazyk: angličtina
Rok vydání: 2010
Předmět:
MESH: Signal Transduction
Linkage disequilibrium
Candidate gene
endocrine system diseases
Genes
BRCA2
Gene Expression
Genome-wide association study
Gene mutation
Linkage Disequilibrium
0302 clinical medicine
MESH: Aged
80 and over
MESH: Risk Factors
Risk Factors
Transforming Growth Factor beta
INVESTIGATORS
skin and connective tissue diseases
POPULATION
Medicine(all)
Genetics
MESH: Aged
Aged
80 and over
0303 health sciences
MESH: Middle Aged
MESH: Polymorphism
Single Nucleotide
MESH: Genetic Predisposition to Disease
Middle Aged
BRCA2 Protein
MESH: Linkage Disequilibrium
030220 oncology & carcinogenesis
Female
Signal Transduction
Research Article
Adult
MESH: Mutation
MESH: Gene Expression
GENES
Single-nucleotide polymorphism
[SDV.CAN]Life Sciences [q-bio]/Cancer
Breast Neoplasms
Biology
Polymorphism
Single Nucleotide
OVARIAN-CANCER
PROPHYLACTIC OOPHORECTOMY
03 medical and health sciences
Breast cancer
[SDV.CAN] Life Sciences [q-bio]/Cancer
SDG 3 - Good Health and Well-being
medicine
MESH: Smad3 Protein
Humans
Genetic Predisposition to Disease
COHORT
Smad3 Protein
GENOME-WIDE ASSOCIATION
MESH: Transforming Growth Factor beta
030304 developmental biology
Genetic association
Aged
MESH: Humans
CONSORTIUM
MESH: Adult
ALLELES
medicine.disease
POLYMORPHISM
Cancer and Oncology
MESH: Genome-Wide Association Study
Mutation
MESH: Female
MESH: Breast Neoplasms
MESH: Genes
BRCA2
Genome-Wide Association Study
Zdroj: Breast Cancer Research : BCR
Breast Cancer Research
Breast Cancer Research, BioMed Central, 2010, 12 (6), pp.R102. ⟨10.1186/bcr2785⟩
Breast cancer research, 12(6). BioMed Central
Breast Cancer Research, 2010, 12 (6), pp.R102. ⟨10.1186/bcr2785⟩
Breast Cancer Research; 12(6) (2010)
Breast Cancer Research, 12(6), R102
Breast Cancer Research, 12(6). BioMed Central Ltd.
Breast cancer research, 12(6):102. BioMed Central Ltd.
ISSN: 1465-5411
1465-542X
DOI: 10.1186/bcr2785⟩
Popis: Introduction: Current attempts to identify genetic modifiers of BRCA1 and BRCA2 associated risk have focused on a candidate gene approach, based on knowledge of gene functions, or the development of large genome-wide association studies. In this study, we evaluated 24 SNPs tagged to 14 candidate genes derived through a novel approach that analysed gene expression differences to prioritise candidate modifier genes for association studies.Methods: We successfully genotyped 24 SNPs in a cohort of up to 4,724 BRCA1 and 2,693 BRCA2 female mutation carriers from 15 study groups and assessed whether these variants were associated with risk of breast cancer in BRCA1 and BRCA2 mutation carriers.Results: SNPs in five of the 14 candidate genes showed evidence of association with breast cancer risk for BRCA1 or BRCA2 carriers (P Conclusions: This study provides evidence that the SMAD3 gene, which encodes a key regulatory protein in the transforming growth factor beta signalling pathway and is known to interact directly with BRCA2, may contribute to increased risk of breast cancer in BRCA2 mutation carriers. This finding suggests that genes with expression associated with BRCA1 and BRCA2 mutation status are enriched for the presence of common genetic modifiers of breast cancer risk in these populations.
Databáze: OpenAIRE
Externí odkaz: